Who
William D. Clark
Director
Company insider
Files Form 4 as: Director, iBio; Director, Aldeyra Therapeutics; President and CEO, Genocea Biosciences; Director, X4 Pharmaceuticals; Sr. VP, Chief Business Officer, Vanda Pharmaceuticals.
In numbers
- Trades disclosed
- 159
- Buys
- 6
- Sells
- 17
- Bought
- $119K
- Sold
- $3.5M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 7 Nov 2006
- Last trade
- 14 Oct 2026
- Last filed
- 15 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 15 Oct 2026 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,323 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,323 at $0.00 | filing |
| 20 Nov 2025filed 24 Nov 2025 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 17 Apr 2025filed 18 Apr 2025 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,760 at $0.00 | filing |
| 10 Jan 2025filed 13 Jan 2025 | IBIO iBioBiotechnology | SEC FORM 4 Bought | $4,9991,838 at $2.72 | filing |
| 21 Nov 2024filed 25 Nov 2024 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —18,900 at $0.00 | filing |
| 2 Jun 2022filed 3 Jun 2022 | Genocea Biosciences | SEC FORM 4 Sold | $2414,023 at $0.06 | filing |
| 31 May 2022filed 2 Jun 2022 | Genocea Biosciences | SEC FORM 4 Sold | $7,035117,244 at $0.06 | filing |
| 4 Apr 2022filed 5 Apr 2022 | Genocea Biosciences | SEC FORM 4 Sold | $4,9053,924 at $1.25 | filing |
| 16 Mar 2022filed 17 Mar 2022 | Genocea Biosciences | SEC FORM 4 Sold | $13K11,435 at $1.10 | filing |
| 15 Mar 2022filed 17 Mar 2022 | Genocea Biosciencesoption or derivative | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 15 Mar 2022filed 17 Mar 2022 | Genocea Biosciences | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 9 Dec 2021filed 13 Dec 2021 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —109,000 at $0.00 | filing |
| 23 Aug 2021filed 25 Aug 2021 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Jun 2021filed 16 Mar 2022 | Genocea Biosciences | SEC FORM 4 Sold | $4,6382,080 at $2.23 | filing |
| 2 Apr 2021filed 16 Mar 2022 | Genocea Biosciences | SEC FORM 4 Sold | $10K3,794 at $2.71 | filing |
| 15 Mar 2021filed 17 Mar 2021 | Genocea Biosciences | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name William D. Clark; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.